Cumberland Pharmaceuticals (CPIX) news
Recent news
Cumberland Pharmaceuticals Q2 adjusted EPS USD -0.2
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported an adjusted earnings loss of $0.20 per diluted share for the second quarter of 2026, according to its recent financial results. This represents a decline compared to adjusted earnings of $0.18 per diluted share in the same period in 2025. The…
AInvest Wire · Aug 4, 2026Cumberland Pharmaceuticals - authorizes open-market share repurchase program of up to $5 mln
Cumberland Pharmaceuticals Inc. has announced the authorization of an open-market share repurchase program, with a maximum value of $5 million . The program, which is subject to market conditions and other factors, allows the company to repurchase shares of its common stock in compliance with…
AInvest Wire · Jul 13, 2026Cumberland Pharmaceuticals closes transaction with Apotex
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has completed a strategic transaction with Apotex, a Canadian-based pharmaceutical company, to integrate Cumberland’s U.S. branded pharmaceutical business into Apotex’s portfolio. Under the terms of the agreement, Apotex acquired Cumberland’s line of…
AInvest Wire · Jul 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.